Today: 14 April 2026
Diageo stock rises as Kenyan court delays hearing on $2.3 billion EABL sale to Asahi
9 January 2026
1 min read

Diageo stock rises as Kenyan court delays hearing on $2.3 billion EABL sale to Asahi

LONDON, Jan 9, 2026, 10:46 GMT — Regular session

  • Diageo shares rose about 2% in London after a Kenyan court pushed a hearing on a bid to halt its EABL sale to Jan. 20
  • The $2.3 billion deal to sell Diageo’s 65% stake in East African Breweries to Asahi is facing a legal challenge from local distributor Bia Tosha
  • Investors are watching the Jan. 20 court date and Diageo’s Feb. 25 interim results for updates on cash, debt and demand

Diageo (DGE.L) shares rose on Friday after a Kenyan court postponed a hearing on a bid to block the drinks maker’s $2.3 billion sale of East African Breweries to Japan’s Asahi Holdings. The stock was up about 2% at 1,634 pence in mid-morning trade.

The case lands at a touchy moment for Diageo, which has been leaning on asset sales to bring in cash and curb debt. A delay in one of its bigger disposals would complicate that timetable.

Investors have also been watching whether spirits demand is steadying, particularly in the United States. That puts more weight on anything that shifts the company’s cash inflow, even if it is far from Diageo’s core markets.

Kenya’s High Court moved the hearing to Jan. 20. Judge Bahati Mwamuye said the parties could take preliminary steps such as regulatory approvals — sign-offs from watchdogs — but could not finalise the transaction before that date, and deal parties still expect completion in the second half of this year. 

The challenge was filed this week by beer distributor Bia Tosha over litigation dating back to 2016. East African Breweries, which is listed in Nairobi, said the case had no factual or legal link to the transaction and added that it and its Kenyan unit could defend any litigation; the sale values EABL at $4.8 billion and would leave Diageo with no direct stake in the African beer business. 

Diageo was last at 1,633.9 pence, up 1.99% on the day, after closing at 1,602.0 pence on Thursday. The stock fell 4.08% on Wednesday and hit an intraday low of 1,564.0 pence, near the bottom of its 52-week range. 

The broader FTSE 100 was up about 0.4% on the session. 

But the legal fight is not over. A tougher ruling, or a longer timetable, could still slow the deal and push out cash proceeds at a time when investors want clearer signs on debt reduction and sales momentum.

The next court hearing is due Jan. 20. Diageo is scheduled to report interim results on Feb. 25, when investors will look for updates on U.S. demand, tariffs and cash generation. 

Stock Market Today

  • Beware the 'buy the dip' trap amid market volatility
    April 14, 2026, 5:22 PM EDT. Investors are cautioned against the popular strategy to "buy the dip," which can lead to poor returns unless one is an exceptional market timer. The MSCI Canada Index and global markets saw dips in March due to geopolitical tensions, but holding cash waiting for dips carries the risk of missing out on gains as inflation erodes cash value. The article highlights that markets pre-price events quickly and do not wait for investors. Leveraging to buy dips increases risks from interest costs and potential margin calls. Historical data shows fund flows rarely predict market direction, with notable cases in 2000 and 2009 underlining this. The piece underscores that relying solely on dip-buying, especially in bear markets, can be perilous without precise timing or understanding market cycles.

Latest article

Nvidia Kills PC Maker Acquisition Rumor, Sending Dell and HP Stocks Back Down

Nvidia Kills PC Maker Acquisition Rumor, Sending Dell and HP Stocks Back Down

14 April 2026
Nvidia denied reports it is in talks to acquire any PC maker, calling a media claim “false.” The rumor had sent Dell and HP shares higher Monday before both fell Tuesday, while Nvidia stock rose $7.14 to $196.51. Bloomberg said the original report described talks going back over a year. Nvidia is expanding into CPUs and AI inference, increasing competition with Intel and AMD.
Dollar, VIX Sink as U.S.-Iran Talks Spur Risk Rally and Push Tariff Bets Aside

Dollar, VIX Sink as U.S.-Iran Talks Spur Risk Rally and Push Tariff Bets Aside

14 April 2026
The dollar index fell to 98.08, its weakest since March, as renewed U.S.-Iran talks eased demand for havens and pushed the VIX near pre-war levels. Brent crude dropped 4.37% to $95.02 a barrel, while the S&P 500 rose 1.11%. The euro and yen strengthened against the dollar. U.S. producer prices rose 0.5% in March, with gasoline up 15.7%.
Robinhood Stock Surges After Bernstein’s $130 Call, but Truist Flags Revenue Pressure

Robinhood Stock Surges After Bernstein’s $130 Call, but Truist Flags Revenue Pressure

14 April 2026
Robinhood shares rose about 10% Tuesday after Bernstein reaffirmed an Outperform rating and $130 price target, despite Truist cutting its target to $100. The stock traded at $78.75. Bernstein’s revenue and earnings forecasts for 2026 are well above consensus, driven by bullish crypto and prediction market estimates. Robinhood’s event-contract business faces legal uncertainty, with a key court hearing set for April 16.
Oil Prices Slide on Iran Talk Hopes, but Brent and WTI Still Face a Supply Shock

Oil Prices Slide on Iran Talk Hopes, but Brent and WTI Still Face a Supply Shock

14 April 2026
Brent crude fell to $95.02 a barrel and U.S. WTI to $92.60 on Tuesday as traders eyed possible U.S.-Iran talks. Prices had topped $100 a day earlier. The International Energy Agency said global supply plunged by a record 10.1 million barrels per day in March, while banks warned volatility could persist even if the Strait of Hormuz reopens.
Rolls-Royce share price steadies near highs as buyback rolls on and Turkey engine hub takes shape
Previous Story

Rolls-Royce share price steadies near highs as buyback rolls on and Turkey engine hub takes shape

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom
Next Story

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

Go toTop